dextromethorphan hydrobromide

Phase 3Small molecule

Boehringer Ingelheim

dextromethorphan hydrobromide is one of 183 small molecule programs targeting Fatigue. It is currently in Phase 3.

Indications

Total Trials

Active Trials

182

Competitors

Pipeline

Status by Indication[3][1]

Indication

AbortionActive, not recruiting

Chronic PainActive, not recruiting

Breast CancerActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Diabetic Macular EdemaActive, not recruiting

Major Depressive DisorderActive, not recruiting

AbortionPhase 3

Active, not recruiting

Chronic PainPhase 3

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Rheumatoid ArthritisPreclinical

Active, not recruiting

Diabetic Macular EdemaPhase 1/Phase 2

Active, not recruiting

Major Depressive DisorderPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

dextromethorphan hydrobromide

Boehringer Ingelheim

Phase 3

1 2

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 3

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 4

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 5

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 6

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

1 7

Lipegfilgrastim

Merck & Co.

Preclinical

1 8

Tianeptine

Pfizer

Preclinical

1 9

Tetracycline Hydrochloride

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Preclinical

1 10

Leronlimab

CCytoDyn, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Post Operative Pain

NCT05278494

Clinical

Trials by Indication[1]

Fatigue1 trial

Dextromethorphan in Treating Patients With Fatigue Caused by Cancer

Terminated·UUniversity of Medicine and Dentistry of New Jersey·N/A·NCT00176540·30 enrolled

Metastatic Castration-Resistant Prostate Cancer1 trial

A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01017939·34 enrolled

Caffeine1 trial

Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02256813·20 enrolled

Post Operative Pain1 trial

Dextromethorphan for Treatment of Postoperative Pain

Recruiting·NNathanael Heckmann·N/A·NCT05278494·160 enrolled

Abortion1 trial

Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion

Completed·SStudy Investigator-Sponsor·Phase 3·NCT03480009·156 enrolled

10 more indications

Rheumatoid Arthritis1 trial

Efficacy Study of Dextromethorphan to Treat Rheumatoid Arthritis

Completed·TTaichung Veterans General Hospital·N/A·NCT02368093·48 enrolled

Breast Cancer1 trial

Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer

Terminated·MMayo Clinic··NCT00873366·92 enrolled

Chronic pain1 trial

Treatment for Chronic Pain in Patients With Advanced Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00003687·87 enrolled

Patients With Advanced Solid Tumors1 trial

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01218620·17 enrolled

Major Depressive Disorder1 trial

A Trial of Dextromethorphan for Treatment of Major Depressive Disorder

Completed·MMedical University of South Carolina·Phase 1·NCT02860962·4 enrolled

Diabetic Macular Edema1 trial

Dextromethorphan for Diabetic Macular Edema

Completed·NNational Eye Institute (NEI)·Phase 1/2·NCT01441102·7 enrolled

Drug1 trial

Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02182336·23 enrolled

Acute Cough1 trial

Dextromethorphan Pediatric Acute Cough Study

Terminated· Pfizer logo

Pfizer·Phase 4·NCT02651116·131 enrolled

Homeostasis1 trial

Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes Subjects

Completed·PProfil Institut für Stoffwechselforschung GmbH·Phase 2·NCT01441986·20 enrolled

Unspecified1 trial

Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02243553·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for dextromethorphan hydrobromide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dextromethorphan hydrobromide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dextromethorphan hydrobromide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Boehringer Ingelheim

dextromethorphan hydrobromide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Fatigue1 trial

Metastatic Castration-Resistant Prostate Cancer1 trial

Caffeine1 trial

Post Operative Pain1 trial

Abortion1 trial

Rheumatoid Arthritis1 trial

Breast Cancer1 trial

Chronic pain1 trial

Patients With Advanced Solid Tumors1 trial

Major Depressive Disorder1 trial

Diabetic Macular Edema1 trial

Drug1 trial

Acute Cough1 trial

Homeostasis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News